Subramanian Gunasekaran is the founder and CEO of Encoll Corp. (founded in 1994).  He holds three US Patents and has authored fifteen publications in the areas of collagen and biomaterials since the founding of Encoll. Previously, Guna worked as a consultant and scientist for Pfizer’s Orthopedic Division.  He was also employed by the University of Arizona, Department of Surgery, as a Research Scientist and Lecturer.  Guna holds a Ph.D. in Biological Chemistry/Neurophysiology.  He has been a member of the Society for Biomaterials since 1984, actively participating in paper submissions, SIG positions, and organizing a panel discussion for the SFB Annual Meeting in 2018 & 2021.  Guna is accomplished in areas of basic research involving cell culture, pre-clinical animal model development, protein processing, pharmaceutical manufacturing, and the strategic development of ethical drugs and regulatory-approved medical devices.  Additionally, his research includes work in cell culture and animal model development.  Guna has directed a number of programs for the successful development of ethical drug and device products as the head of project design groups and management teams.  He has completed numerous pre-clinical study designs and executions.  He was responsible for regulatory agency interactions (FDA and non-US agencies) for product/device approvals.  With 35 years of experience in GMP manufacturing and related activities (i.e., pharmaceutical and medical device manufacturing), Guna has made significant contributions to the field.